AIM Vaccine Plans Beijing Stock Exchange IPO to Strengthen Capital Base and Expand Operations
AIM Vaccine Co., Ltd. (HKG: 6660), a China-based vaccine developer, has announced plans for an...
Roche Launches cobas MPX-E Test in CE Markets, Consolidating Four-Virus Detection for Enhanced Blood Safety
Roche AG (SWX: ROG, OTCMKTS: RHHBY) has announced the commercial launch of its cobas MPX-E...
NMPA Approves GSK’s Exdensur as First Ultra-Long-Acting Biologic for Severe Eosinophilic Asthma
China’s National Medical Products Administration (NMPA) has approved GlaxoSmithKline plc (GSK, NYSE: GSK)’s Exdensur (depemokimab)...
Kexing Biopharma Secures FDA Clearance for GB19 Clinical Trial in Lupus, Targeting Novel BDCA2 Pathway
Kexing Biopharma (SHA: 688136) announced it has received approval from the U.S. Food and Drug...
Shaanxi Micot Files HKSE Listing Application to Advance Bifunctional Peptide Drug Pipeline
Shaanxi Micot Pharmaceutical Technology Co., Ltd., a Xi’an-based developer of bifunctional and multi-functional peptide therapeutics,...
NMPA Finalizes Conditional Drug Approval Framework to Accelerate Access to Critical Medicines
China’s National Medical Products Administration (NMPA) has announced the review and approval of the “Working...
Dizal Pharmaceutical Reports Record Sales Growth Driven by NRDL Inclusion of Sunvozertinib and Golidocitinib
Dizal Pharmaceutical Co., Ltd. (SHA: 688192) reported exceptional commercial performance in its 2025 financial results,...
NMPA Expands Generic Quality Consistency Evaluation Program with 36 New Reference Drug Specifications
China’s National Medical Products Administration (NMPA) has released its 103rd batch of reference drugs for...
Salubris Pharma Licenses Sintanovo’s Peripherally Restricted KOR Agonist STC007 for Pruritus and Pain Across Greater China
Shenzhen Salubris Pharmaceuticals Co., Ltd. (SHE: 002294) announced an exclusive licensing agreement with Chengdu-based Sintanovo...
China’s Largest Healthcare M&A Fund Acquires Pediatrix Therapeutics, Bolstering Pediatric Specialty Pharma Portfolio
The Beijing State-owned Capital E-town CBC Industrial Investment Fund Partnership Enterprise, China’s largest specialized healthcare...
Hansoh Pharma’s Uplizna Gains Third NMPA Approval in China for Generalized Myasthenia Gravis, Expanding CD19 Antibody Franchise
Hansoh Pharmaceutical Group Co., Ltd. (HKG: 3692) announced that China’s National Medical Products Administration (NMPA)...
Insilico Medicine and Eli Lilly Forge $2.75B AI Drug Discovery Partnership, Centered on Best-in-Class Oral Therapeutic
Insilico Medicine (HKG: 3696), a pioneer in generative artificial intelligence (AI)-driven drug discovery, announced a...
Huadong Medicine’s YY001 Becomes World’s First Recombinant Botulinum Toxin Approved in China for Glabellar Lines
Huadong Medicine Co., Ltd. (SHE: 000963) announced that China’s National Medical Products Administration (NMPA) has...
AstraZeneca’s Tezspire Gains Dual NMPA Approvals in China for Severe Asthma and Nasal Polyps Based on Pivotal Phase III Data
AstraZeneca plc (NYSE: AZN) announced that China’s National Medical Products Administration (NMPA) has approved Tezspire®...
Medtronic’s Stealth AXiS Surgical System Gains FDA Approval for Cranial and ENT Procedures, Expanding Beyond Spine
Medtronic plc (NYSE: MDT) announced it has received U.S. Food and Drug Administration (FDA) marketing...
Jenscare Completes First-in-Human Study of iJensRobo Robot-Assisted Tricuspid Valve Replacement System
Jenscare Scientific Co., Ltd. (HKG: 9877), a pioneer in structural heart interventions, announced the successful...
Clover Biopharmaceuticals Completes Enrollment in Phase II Trial of Trimer-Tag Respiratory Combination Vaccines for Older Adults
Clover Biopharmaceuticals Ltd. (HKG: 2197) announced the completion of subject enrollment in a Phase II...
J&J’s Darzalex SC Becomes First Oncology Injectable in Europe Approved for Patient Self-Administration
Johnson & Johnson (J&J, NYSE: JNJ) announced that the Committee for Medicinal Products for Human...
Novartis to Acquire Excellergy for Up to $2 Billion, Adding Next-Gen Anti-IgE Antibody Exl-111 to Immunology Pipeline
Novartis AG (NYSE: NVS) announced an agreement to acquire Excellergy, Inc., a U.S.-based biotech, for...
GSK’s Bepirovirsen Receives EMA Review Acceptance for Chronic Hepatitis B, Pioneering Triple-Mechanism ASO Therapy
GlaxoSmithKline plc (GSK, NYSE: GSK) announced that the European Medicines Agency (EMA) has accepted for...